Valuation: Pelthos Therapeutics Inc.

Market Cap 3.6Cr 3.22Cr 2.97Cr 2.69Cr 5.03Cr 341.67Cr 5.13Cr 35Cr 14Cr 179.23Cr 14Cr 13Cr 567.09Cr P/E 2026 *
-0.52x
P/E 2027 * -2.42x
Enterprise Value 3.6Cr 3.22Cr 2.97Cr 2.69Cr 5.03Cr 341.67Cr 5.13Cr 35Cr 14Cr 179.23Cr 14Cr 13Cr 567.09Cr EV / Sales 2026 *
0.58x
EV / Sales 2027 * 0.33x
Free-Float
49.95%
Yield 2026 *
-
Yield 2027 * -
1 day-43.17%
1 week-44.71%
1 month-55.26%
3 months-67.20%
6 months-62.40%
Current year-69.68%
1 week 9.02
Extreme 9.02
20.5
1 month 9.02
Extreme 9.02
22.95
Current year 9.02
Extreme 9.02
30.99
1 year 9.02
Extreme 9.02
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Sell

Director

-558 0.0161%
02/10/26 Sell

Chairman

-797 0.0229%
02/10/26 Sell

Director

-786 0.0226%
Change 5-day change 1-year change 3-year change Capi.($)
-43.17%-44.71%-71.52% - 3.6Cr
+3.19%+11.31%+64.28%+155.91% 1,26300Cr
-0.73%+3.56%+44.65%+84.17% 66TCr
+1.41%+3.24%+35.25%+108.88% 52TCr
+0.42%+3.20%+55.81%+72.50% 39TCr
+2.18%+2.93%+73.90%+45.59% 37TCr
+1.12%+4.52%+34.76%+58.24% 31TCr
+6.96%+8.86%+11.95%+36.20% 29TCr
+1.15%+6.09%+56.15%+82.25% 25TCr
+3.06%+9.38%+42.48%+117.32% 21TCr
Average -2.44%+0.84%+34.77%+84.56% 42.62TCr
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 6.24Cr 5.59Cr 5.14Cr 4.66Cr 8.71Cr 592.04Cr 8.88Cr 61Cr 25Cr 310.57Cr 23Cr 23Cr 982.65Cr 11Cr 9.71Cr 8.94Cr 8.1Cr 15Cr 1.03TCr 15Cr 106.43Cr 43Cr 539.84Cr 41Cr 40Cr 1.71TCr
Net income -6.56Cr -5.87Cr -5.41Cr -4.9Cr -9.16Cr -622.44Cr -9.34Cr -64Cr -26Cr -326.52Cr -25Cr -24Cr -1.03TCr -2.88Cr -2.58Cr -2.37Cr -2.15Cr -4.02Cr -273.03Cr -4.1Cr -28Cr -11Cr -143.22Cr -11Cr -11Cr -453.16Cr
Net Debt - -
Projected Income Statement - Annual - Pelthos Therapeutics Inc.
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
30/26/30 $9.400 -43.17% 2,42,032
29/26/29 $16.54 +5.08% 14,741
28/26/28 $15.74 +8.55% 49,702
27/26/27 $14.50 -4.61% 73,232
26/26/26 $15.20 -10.59% 22,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Pelthos Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.400USD
Average target price
49.57USD
Spread / Average Target
+427.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pelthos Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. PTHS Stock